Frankfurt - Delayed Quote ? EUR Sedana Medical AB (publ) (7D2A.F) Follow Compare 0.8930 -0.0100 (-1.11%) As of 9:15 AM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Sedana Medical AB (FRA:7D2A) Q3 2024 Earnings Call Highlights: Record Sales and Strategic Moves ... Despite challenges, Sedana Medical AB (FRA:7D2A) reports its highest Q3 net sales and raises full-year sales guidance, driven by strong market performance and strategic acquisitions. GuruFocus.com ? 23 days ago 7D2A.F -1.11% Sedana Medical completes patient recruitment for its clinical program in the US Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025. PR Newswire ? 5 months ago SEDANA.ST Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025. PR Newswire ? 6 months ago SEDANA.ST Performance Overview Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return 7D2A.F OMX Stockholm 30 Index YTD -56.52% +3.20% 1-Year -37.68% +12.56% 3-Year -90.13% +4.30%
